Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2024 Category: Pharmaceuticals Source Type: clinical trials

Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
Conditions:   Lyme Disease;   Post-Treatment Lyme Disease;   Chronic Lyme Disease;   Tick-Borne Infections;   Pregnancy Complications;   Child Development Intervention:   Other: Neurodevelopmental assessments and follow-up Sponsors:   Children's National Research Institute;   Clinical Trials Network for Lyme and Other Tick-Borne Diseases;   Steven & Alexandra Cohen Foundation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
Condition:   Lyme Disease Interventions:   Biological: mRNA-1975;   Biological: mRNA-1982;   Biological: Placebo Sponsor:   ModernaTX, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials